Study of Carfilzomib and Vorinostat for Relapsed or Refractory Lymphoma

Part of paid clinical trials in Rochester, New York.

Sponsor
University of Rochester
Study ID
NCT01276717
Phase
PHASE1
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Drug: Carfilzomib — DRUG
    Carfilzomib 30 minutes infusion daily for days 1, 2, 8, 9, 15, 16, Every 28 days. A maximum of 13 cycles will be administered.
  • Vorinostat — DRUG
    Vorinostat by mouth twice daily on days 1, 2, 3, 8, 9, 10, 15, 16 and 17. Maximum 13 cycles.

Study Details

This will be a phase I study of carfilzomib in combination with vorinostat in patients with relapsed/refractory B-cell lymphomas. Combination therapy with proteosome inhibitor PR-171 and HDAC inhibitors is highly synergistic in primary DLBCL cells, and both classes of drugs can also synergize powerfully to induce cell death in bortezomib-resistant cells. The purpose of this study is to see if vorinostat can combine with carfilzomib and to safely find the recommended phase II dose.

Key Dates

Start date
Jan 31, 2011
Status verified
Dec 2015
Primary completion
Jul 31, 2013
Completion
Jan 31, 2015

Study Design

Enrollment
20 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Vorinostat + Carfilzomib

Primary Outcome Measure

Number of Participants who experience Adverse Events as a Measure of Safety and Tolerability [ Time Frame: From date of study entry until the 30 days after the last dose of study treatment. ]

Locations (2)

FacilityCityStateZIPSite coordinators
University of RochesterRochesterNew York14642-
Virginia Commonwealth University Massey Cancer CenterRichmondVirginia23298-

Find similar trials in Rochester, NY

By research site
University of Rochester· Rochester, NYVirginia Commonwealth University Massey Cancer Center· Richmond, VA

Related Studies